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Transgenic overexpression of GTP 
cyclohydrolase 1 in cardiomyocytes 
ameliorates post-infarction cardiac 
remodeling
Yanan Liu1,7, Shelley L. Baumgardt1, Juan Fang2, Yang Shi5, Shigang Qiao1, Zeljko J. 
Bosnjak1,3, Jeannette Vásquez-Vivar4, Zhengyuan Xia6, David C. Warltier1, Judy R. Kersten1 & 
Zhi-Dong Ge  1
GTP cyclohydrolase 1 (GCH1) and its product tetrahydrobiopterin play crucial roles in cardiovascular 
health and disease, yet the exact regulation and role of GCH1 in adverse cardiac remodeling after 
myocardial infarction are still enigmatic. Here we report that cardiac GCH1 is degraded in remodeled 
hearts after myocardial infarction, concomitant with increases in the thickness of interventricular 
septum, interstitial fibrosis, and phosphorylated p38 mitogen-activated protein kinase and decreases 
in left ventricular anterior wall thickness, cardiac contractility, tetrahydrobiopterin, the dimers of nitric 
oxide synthase, sarcoplasmic reticulum Ca2+ release, and the expression of sarcoplasmic reticulum 
Ca2+ handling proteins. Intriguingly, transgenic overexpression of GCH1 in cardiomyocytes reduces 
the thickness of interventricular septum and interstitial fibrosis and increases anterior wall thickness 
and cardiac contractility after infarction. Moreover, we show that GCH1 overexpression decreases 
phosphorylated p38 mitogen-activated protein kinase and elevates tetrahydrobiopterin levels, the 
dimerization and phosphorylation of neuronal nitric oxide synthase, sarcoplasmic reticulum Ca2+ 
release, and sarcoplasmic reticulum Ca2+ handling proteins in post-infarction remodeled hearts. Our 
results indicate that the pivotal role of GCH1 overexpression in post-infarction cardiac remodeling is 
attributable to preservation of neuronal nitric oxide synthase and sarcoplasmic reticulum Ca2+ handling 
proteins, and identify a new therapeutic target for cardiac remodeling after infarction.
Myocardial infarction (MI) is one of the main health and economic problems and the leading cause of death in 
the Western world1, 2. Following MI, cardiac remodeling occurs progressively in untreated patients with large 
MI3. Post-infarction cardiac remodeling is now recognized as central in the pathophysiology of advancing heart 
failure3–5. Slowing or reversing post-infarction cardiac remodeling is emerging as a therapeutic strategy for pre-
venting the development of heart failure after MI5, 6. The results of conventional therapy directed at the reduction 
of cardiac remodeling after MI are disappointing7, 8. New approaches, such as stem/progenitor cell-based cardiac 
regeneration therapies, are shown to attenuate cardiac remodeling and/or dysfunction after MI in small animal 
models9, 10. However, in humans the therapeutic effects of stem/progenitor cell transplantation on post-infarction 
myocardium remain uncertain11. The search for new therapeutic targets to slow or reverse cardiac remodeling 
after MI is of importance for the precision treatment of cardiac remodeling.
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GTP cyclohydrolase 1 (GCH1) is known as the first and rate-limiting enzyme in de novo biosynthesis of 
tetrahydrobiopterin (BH4), an essential co-factor for nitric oxide synthase (NOS), tryptophan hydroxylase, phe-
nylalanine hydroxylase, and tyrosine hydroxylase12. Recent studies find that GCH1 and BH4 play important roles 
in the regulation of the expression and function of NOS, the function of the sarcoplasmic reticulum (SR) and 
mitochondria, oxidative/nitrosative stress, and myocyte contractility and relaxation in normal myocardium13–15. 
However, GCH1 proteins are decreased due to increased degradation of GCH1 by 26S proteasome or/and 
decreased biosynthesis during cardiovascular disease and in diabetes, Parkinson’s disease, or aging16–18. In intact 
animals, the deficiency or inhibition of GCH1 proteins or GCH1 gene mutations result in vascular endothelial 
dysfunction, systemic hypertension, pulmonary hypertension, cardiac dysfunction, or short lifespan13, 16, 19–25. 
At cellular and molecular level, insufficient GCH1 proteins lead to dysregulation of biopterins, NOS, and p38 
mitogen-activated protein kinase (p38 MAPK), suppression of the SR and mitochondrial function, and oxidative/
nitrosative stress13, 14, 16, 21–23, 26. Previous studies report that the activity of 26S proteasome, a ubiquitous enzyme 
responsible for the degradation of GCH116, is elevated in post-infarction myocardium27. It is known that dysreg-
ulation of NOS isoforms, phosphorylated p38 mitogen-activated protein kinase (p-p38 MAPK), abnormalities 
in the SR and mitochondrial function, and oxidative/nitrosative stress contribute to the development of cardiac 
remodeling and heart failure28–31. However, how GCH1 is involved in cardiac remodeling and function after MI 
remains unclear.
In the present study, we examined the regulation and role of GCH1 in left ventricular remodeling after MI in 
mice and explored the molecular mechanisms underlying regulation of post-infarction cardiac remodeling by 
GCH1. First, cardiac GCH1 mRNA and proteins were kinetically measured in C57BL/6 wild-type (WT) mice 
from 1 to 12 weeks after MI. Secondly, the geometry and function of the left ventricle (LV), infarct size, and inter-
stitial fibrosis were compared in the transgenic (Tg) mice with cardiomyocyte-specific overexpression of human 
GCH1 gene with those in C57BL/6 mice 4 weeks after MI or sham surgery32, 33. Lastly, to study the signaling path-
ways linking GCH1 with cardiac remodeling, we determined cardiac BH4 concentrations, free Ca2+ and SR Ca2+ 
release in cardiomyocytes in the presence and absence of isoproterenol, and the expression of microRNA-21, p38 
MAPK, 3 isoforms of NOS, and SR Ca2+ handling proteins in Tg and C57BL/6 mice 4 weeks after MI or sham 
surgery. Our results indicate that GCH1 degradation contributes to the pathogenesis of cardiac remodeling and 
dysfunction after MI. More importantly, cardiomyocyte-specific overexpression of human GCH1 gene favorably 
regulates BH4, the dimerization and phosphorylation of neuronal NOS (nNOS), free Ca2+ and SR Ca2+ release in 
cardiomyocytes, and the expression of SR Ca2+ handling proteins, thereby preventing the development of cardiac 
remodeling after MI.
Results
Cardiac GCH1 is decreased in WT mice after MI. We first examined whether cardiac GCH1 gene and 
proteins are regulated in remodeled hearts after MI in C57BL/6 mice. C57BL/6 mice underwent permanent liga-
tion of the left coronary artery to make MI or sham surgery as control. Coronary artery ligation resulted in sig-
nificant changes in heart shape and increases in heart size from 2 to 12 weeks after MI (P < 0.05 between sham 
WT and MI WT groups, n = 6–8 mice/group) (Fig. 1A). We used a noninvasive transthoracic echocardiography 
to measure the wall thickness of the LV at 0 (baseline), 1, 2, 4, 8, and 12 weeks after surgery. The thickness of left 
ventricular wall was comparable between sham WT and MI WT groups at baseline (P > 0.05, n = 10 mice/group) 
(Fig. 1B and C). Compared with sham WT groups, anterior wall was thinner at both end diastole and end systole, 
and interventricular septum was thicker at both end diastole and end systole from 2 to 12 weeks after surgery 
(P < 0.05, n = 8–10 mice/group). After echocardiographic examination was completed, the LVs were harvested 
for determination of GCH1 mRNA and proteins. The levels of GCH1 mRNA and proteins were comparable 
between MI WT and sham WT groups at baseline. The levels of GCH1 mRNA were not changed over time in 
both MI WT and sham WT groups 1 to 12 weeks after surgery (Fig. 1D and E). However, the expression of GCH1 
proteins was significantly decreased 2 to 12 weeks after MI (P < 0.05 versus 0 week, n = 6 mice/group) (Fig. 1F 
and 1G). These results suggest that GCH1 proteins are degraded in post-infarction remodeled myocardium of 
WT mice.
Cardiomyocyte-specific overexpression of GCH1 diminishes cardiac remodeling after MI. To 
study whether increases in cardiac GCH1 can attenuate cardiac remodeling after MI, we made infarction in Tg 
and C57BL/6 WT mice by ligating the left coronary artery. Sham control animals underwent the same procedures 
except coronary artery ligation. The geometry of the LV was evaluated with an echocardiography at 0 (baseline), 
2, and 4 weeks after surgery. Heart rate, the thickness of left ventricular anterior and posterior walls, internal 
diameters, and fractional shortening were comparable among 4 groups of mice at baseline (P > 0.05, n = 12 mice/
group) (Fig. 2). Compared with sham WT groups, the thickness of LV anterior wall at both end diastole and end 
systole and fractional shortening were significantly decreased, whereas the thickness of interventricular septum 
at both end diastole and end systole and the internal diameters of left ventricular chamber were significantly 
increased in MI WT but not MI Tg groups 4 weeks after MI (P < 0.05, n = 8–12 mice/group]. There were no 
significant differences in the wall thickness and diameter of the LV and fractional shortening between MI Tg 
and sham WT groups throughout the experiments (P > 0.05). These results indicate that GCH1 overexpression 
attenuates cardiac remodeling after MI.
GCH1 overexpression attenuates infarct size and interstitial fibrosis. Infarct size, LV diame-
ters, and interstitial fibrosis in remodeled hearts are associated with the development of heart failure3, 34. We 
measured infarct size, LV internal diameters, interstitial fibrosis, and myocyte cross-sectional area in Masson’s 
trichrome-stained sections of mouse hearts. The sections obtained from sham WT and sham Tg mice showed 
no infarction (Fig. 3A). In contrast, the sections obtained from MI WT mice 4 weeks after MI revealed an 
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anteroapical infarct that extended into the anterolateral wall (infarct zone, IZ) at the level of the papillary muscle, 
whereas the interventricular septum (remote zone, RZ) was generally sparred (Fig. 3A). Infarct size expressed as a 
percentage of infarct circumference/LV circumference was 38 ± 4%, and LV internal diameter at mid-ventricular 
level was 6.1 ± 0.3 mm (n = 10 mice) in MI WT group (Fig. 3B and C). GCH1 overexpression significantly 
decreased infarct size and LV internal diameters to 19 ± 2% and 4.5 ± 0.4 mm (P < 0.05 between MI Tg and MI 
WT groups, n = 10 mice/group), respectively (Fig. 3B and C). In RZ of the LV, interstitial fibrosis and myocyte 
cross-sectional area were significantly increased in MI WT but not MI Tg groups compared with sham WT 
groups (Fig. 3D,E and F).
Either MicroRNA-21 or p38 MAPK is associated with the pathogenesis of interstitial fibrosis35, 36. To study 
the molecular mechanisms underlying reduced interstitial fibrosis by GCH1 overexpression, we determined the 
expression of microRNA-21 and p38 MAPK in the RZ of myocardium in WT and Tg mice 4 weeks after MI or 
sham surgery (Fig. 4A). Compared with sham WT groups, microRNA-21 levels and the ratio of p-p38 MAPK/p38 
MAPK were significantly increased in MI WT groups (P < 0.05, n = 5 mice/group) (Fig. 4B,C and D). There were 
no significant differences in myocardial microRNA-21 levels and the ratio of p-p38/p38 MAPK between sham Tg 
Figure 1. Wild-type (WT) mice developed cardiac remodeling and lost GTP cyclohydrolase 1 (GCH1) proteins 
following myocardial infarction (MI). (A) Time-dependent changes in mouse hearts after MI or sham surgery 
(n = 6–8 mice/group). Top: representative images of mouse hearts at baseline (0), 1, 2, 4, 8, and 12 weeks 
after operation. The vertical scale bar indicates 4 mm, and the horizontal scale bar indicates 2 mm. Bottom: 
the area of the hearts after MI or sham surgery; (B) The anterior wall thickness of the left ventricule after MI 
or sham surgery (n = 8–10 mice/group); (C) The thickness of interventricular septum following MI or sham 
surgery (n = 8–10 mice/group); (D) Representative PCR bands showing the expression of GCH1 mRNA and 
the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), at 0, 1, 2, 4, 8, and 12 weeks 
after MI; (E) GCH1 mRNA normalized to GAPDH (n = 6 mice/group); (F) Representative Western blot bands 
showing the expression of cardiac mouse GCH1 proteins and GAPDH proteins in WT mice following MI; (G) 
Expression of mouse GCH1 proteins normalized to GAPDH proteins (n = 6 mice/group). *P < 0.05 versus 
sham WT groups at corresponding time points (A,B and C) or 0 weeks (G).
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and sham WT groups (P > 0.05). Interestingly, GCH1 overexpression significantly decreased the ratio of p-p38/
p38 MAPK (P < 0.05 between MI Tg and MI WT groups) but not microRNA-21 levels after MI (Fig. 4B and D). 
Thus, GCH1 overexpression inhibits the formation of interstitial fibrosis through reduction of p-p38 MAPK.
GCH1 overexpression improves cardiac function after MI. The Langendorff-perfused isolated mouse 
hearts offer a highly thorough and reliable model for the analysis of myocardial contractility and relaxation37, 38. 
Since many factors can influence cardiac performance in vivo (Fig. S1), we evaluated the effects of GCH1 overex-
pression on cardiac function after MI in the isovolumic, buffer-perfused, balloon-in-LV Langendorff preparation. 
LV end-systolic pressure and the value of + dP/dt (the rate of LV pressure rise) were significantly smaller in MI 
WT than sham WT groups (P < 0.05, n = 8–11 hearts/group) (Fig. 5A,B and C). Compared with MI WT groups, 
they were significantly elevated in MI Tg groups (P < 0.05) (Fig. 5B and C), suggesting that GCH1 overexpression 
elevates cardiac contractility after MI. LV end-diastolic pressure was comparable among 4 groups of mice at 20, 
25, 30, and 35 µl of LV volume (P > 0.05, n = 8–11 hearts/group) (Fig. 5D). Compared with sham WT groups, LV 
end-diastolic pressure was significantly decreased in MI WT but not MI Tg groups from 40 to 70 µl of LV volume 
(Fig. 5D), suggesting that GCH1 overexpression improves cardiac relaxation after MI.
Body weight was comparable among 4 groups of mice 4 weeks after MI or sham surgery (Table S2). However, 
the ratios of heart weight/body weight, LV weight/body weight, and lung weight/body weight were significantly 
higher in MI WT than sham WT groups (P < 0.05, n = 8–10 mice/group) (Fig. 5E,F and G). These parameters 
were comparable between sham Tg and sham WT groups. Compared with MI WT groups, the ratios of heart 
weight/body weight, LV weight/body weight, and lung weight/body weight were significantly decreased in MI Tg 
groups (Table S2), suggesting that GCH1 overexpression reduces LV mass after MI and lung edema arising from 
left ventricular dysfunction.
GCH1 overexpression reduces cardiomyocyte Ca2+ overload after MI. Intracellular free Ca2+ plays 
a central part in regulating excitation-contraction coupling of cardiac muscle and in modulating systolic and dias-
tolic function in the heart39. Perturbations in intracellular Ca2+ handling contribute to contractile dysfunction in 
Figure 2. Effects of GTP cyclohydrolase 1 (GCH1) overexpression on cardiac remodeling 4 weeks after 
myocardial infarction (MI). (A) Heart rate; (B) The anterior wall thickness of the left ventricle (LV) at end 
diastole: (C) The anterior wall thickness of the LV at end systole; (D) The interventricular septum thickness of 
the LV at end diastole: (E) The interventricular septum thickness of the LV at end systole; (F) LV end-diastolic 
diameter; (G) LV end-systolic diameter; (H) Fractional shortening; (I) Figure legend: sham WT (wild-type), 
MI WT, sham Tg (GCH1 transgene), and MI Tg; (J) representative M-mode echocardiograms showing anterior 
wall, LV chamber, and interventricular septum in the mice 4 weeks after MI. *P < 0.05 versus sham WT groups; 
†P < 0.05 versus MI WT groups (n = 8–12 mice/group).
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various models of cardiac dysfunction40, 41. We measured intracellular free Ca2+ in Fura-2-loaded cardiomyocytes 
isolated from WT and Tg mice 4 weeks after MI or sham surgery (Fig. 6). There were no significant differences 
in basal Ca2+ concentrations and time to 50% decay (T50) of Ca2+ transients elicited by electric field stimulation 
among 4 groups of mice (P > 0.05, n = 63–66 cells/group) (Fig. 6A and C). Compared with sham WT group, Ca2+ 
transient amplitude was greater in MI WT but not MI Tg groups (P < 0.05) (Fig. 6B).
In intact animals, cardiomyocytes live in the presence of β-adrenergic agonists such as epinephrine, nor-
epinephrine, and dopamine42. We further determined intracellular [Ca2+]I in the presence of the β-adrenergic 
agonist, isoproterenol (Fig. 6D). Application of 20 nM isoproterenol to cardiomyocytes elevated basal Ca2+ levels 
and Ca2+ transient amplitude and decreased T50 decay of Ca2+ transients elicited by electricity in cardiomyocytes 
isolated from all mice. In the presence of isoproterenol, basal [Ca2+]I and T50 decay of Ca2+ transients were 
comparable among 4 groups of mice (P > 0.05) (Fig. 6E and G). Compared with sham WT group, Ca2+ tran-
sient amplitude was significantly increased in MI WT but not in MI Tg group (P < 0.05, n = 63–66 cells/group) 
(Fig. 6F). There were no significant differences in Ca2+ transient amplitude between MI Tg and sham WT groups 
(P > 0.05) (Fig. 6F). These results suggest that MI WT cardiomyocytes have excessive cytoplasm Ca2+ (Ca2+ over-
load), and GCH1 overexpression reduces Ca2+ overload after MI.
GCH1 overexpression preserves SR Ca2+ release and SR Ca2+ handling proteins after MI. The 
SR plays critical roles in intracellular Ca2+ release and re-uptake43. To study whether Ca2+ overload also exists in 
the SR, we quantified SR Ca2+ release by applying 10 mM caffeine to cardiomyocytes in 0 Na+ and 0 Ca2+ Tyrode 
buffer16 (Fig. 7A). In the presence of 20 nM isoproterenol, SR Ca2+ release was significantly lower in MI WT 
group (P < 0.05, n = 63–66 cells/group) but not in MI Tg group than sham WT group (Fig. 7C). There were no 
significant differences in SR Ca2+ release between MI Tg and sham WT groups (P > 0.05). These results indicate 
that SR Ca2+ release is impaired in MI WT cardiomyocytes, and GCH1 overexpression preserves SR Ca2+ release 
after MI.
Figure 3. Effects of GTP cyclohydrolase 1 (GCH1) overexpression on myocardial infarct size and interstitial 
fibrosis after myocardial infarction (MI). (A) Representative Masson’s trichrome-stained cross section of the 
heart showing infarct area with fibrosis. The scale bar shows 2 mm, and the arrows indicate infarct area with 
fibrosis. BZ, border zone; IZ, infarct zone; LV, left ventricle; RV, right ventricle; RZ, remote zone; (B) Infarct size 
expressed as a percentage of infarct circumference/total circumference of the LV; (C) LV internal diameters at 
the papillary muscle levels; (D) Masson’s trichrome-stained myocardium showing interstitial fibrosis. The scale 
bar shows 400 µm, and the arrows indicate fibrosis; (E) Interstitial fibrosis expressed as a percentage of LV area; 
(F) Myocyte cross-sectional area. Mouse hearts were stained with Masson’s trichrome in wild-type (WT) and 
transgenic (Tg) mice 4 weeks after MI or sham surgery. *P < 0.05 versus sham WT groups; †P < 0.05 versus MI 
WT groups; #P < 0.05 versus sham Tg groups (n = 8–10 mice/group).
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 3093  | DOI:10.1038/s41598-017-03234-6
In cardiomyocytes, ryanodine receptors (RyR2) control Ca2+ release from the SR to trigger muscle contrac-
tion, whereas SR Ca2+-ATPase (SERCA2a) re-uptakes Ca2+ from the cytosol into the SR to elicit relaxation43, 44. 
We used Western blot analysis to measure the expression of SR Ca2+ handling proteins in WT and Tg mouse 
hearts 4 weeks after MI or sham surgery. Compared with sham WT groups, the ratios of RyR2/glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and SERCA2a/GAPDH were significant decreased in MI WT (P < 0.05, 
n = 5 mice/group) but not MI Tg groups (Fig. 7E and F). SERCA2a activity is directly regulated by the natu-
rally inhibitory phospholamban (PLB)45. Furthermore, we examined the effects of GCH1 on the expression of 
PLB and SERCA2a. Compared with sham WT group, the ratio of PLB/SERCA2a was not significant altered in 
either MI WT or MI Tg groups (P > 0.05) (Fig. 7G), suggesting that the activity of SERCA2a is not changed in 
post-infarction remodeled myocardium. Thus, decreases in RyR2 and SERCA2a contribute to impaired SR Ca2+ 
release in MI WT mice, and preservation of SR Ca2+ handling proteins by GCH1 overexpression is responsible 
for improvement in the SR Ca2+ release after MI.
GCH1 overexpression elevates cardiac BH4 levels after MI. To examine whether transfer of human 
GCH1 gene effectively elevates the expression of GCH1 proteins in Tg mice, we used Western blot analysis to 
determine the expression of human and mouse GCH1 proteins in post-infarction remodeled hearts. Transfer of 
human GCH1 gene drove GCH1 protein expression in Tg mouse hearts with and without cardiac remodeling 
(Fig. 8A). Compared with sham WT group, the expression of mouse GCH1 proteins was significantly decreased 
in MI WT group 4 weeks after MI, however, the expression of total (human plus mouse) GCH1 proteins was sig-
nificantly elevated in both sham Tg and MI Tg groups (P < 0.05, n = 5–6 mice/group) (Fig. 8A and B).
BH4 plays important roles in cardiovascular health and disease12, 46. GCH1 is the rate-limiting enzyme in de 
novo synthesis of BH412. We quantified cardiac BH4 concentrations with high-performance liquid chromatogra-
phy (HPLC)38. Compared with sham WT groups, myocardial BH4 concentrations were significantly decreased in 
MI WT groups and increased in sham Tg and MI Tg groups (P < 0.05, n = 6 mice/group) (Fig. 8C), which was 
similar to changes in GCH1.
Figure 4. Effects of GTP cyclohydrolase 1 (GCH1) overexpression on microRNA-21 and p38 mitogen-activated 
protein kinase (MAPK) after myocardial infarction (MI). (A) Representative transverse sections of fresh mouse 
hearts showing the positon of tissue sampling for measurements of microRNA-21 and p38 MAPK 4 weeks after 
(MI) or sham surgery. The drawing areas indicate the position of tissue sampling, and the scales indicate 1 mm. 
(B) The expression of microRNA-21 mRNA; (C) representative Western blot bands showing the expression of 
phosphorylated p38 (p-p38) MAPK, total p38 MAPK, and GAPDH; (D) The ratio of phosphorylated p38 (p-
p38) MAPK/p38 MAPK. *P < 0.05 versus sham WT groups; †P < 0.05 versus MI WT groups; #P < 0.05 versus 
sham Tg groups (n = 8–10 mice/group).
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GCH1 overexpression elevates nNOS dimerization and phosphorylation after MI. NOS dys-
regulation is associated with the pathogenesis of cardiac remodeling and dysfunction47, 48. NOS functions only 
in dimeric state49. Thus, we measured the dimers and monomers of three isoforms of NOS: nNOS, eNOS, and 
iNOS, in WT and Tg mouse hearts16. In sham WT mice, the ratios of nNOS dimers/monomers and eNOS dimers/
monomers were 1.6 ± 0.2 and 2.1 ± 0.3 (n = 5 mice/group), respectively (Fig. 9A–D). Both nNOS dimers and 
eNOS dimers were decreased in MI WT groups, whereas both nNOS monomers and eNOS monomers were 
increased in MI WT groups 4 weeks after MI compared sham WT groups. The ratios of nNOS dimers/monomers 
and eNOS dimers/monomers were significantly lower in MI WT than sham WT groups (P < 0.05, n = 5 mice/
group) (Fig. 9B and D). Interestingly, GCH1 overexpression increased dimeric nNOS in not only sham Tg but 
also MI Tg myocardium (P < 0.05 versus MI WT groups, n = 5 mice/group). There were no significant differences 
in the ratio of nNOS dimers/monomers among sham WT, sham Tg and MI Tg groups (P > 0.05). In contrast, the 
ratio of eNOS dimers/monomers was not significantly changed in MI Tg groups compared with MI WT groups 
(P > 0.05). The expression of iNOS dimers was not detected in mouse hearts. The expression of iNOS monomers 
was significantly greater in WT MI than sham WT groups (Fig. 9E and F). There were no significant differences 
in the ratio of iNOS monomers/GAPDH between sham Tg and sham WT groups. GCH1 overexpression sig-
nificantly decreased the expression of iNOS monomers 4 weeks after MI. Dimeric NOS produces NO, whereas 
monomeric NOS generates superoxide49. Compared with sham WT groups, NO and superoxide levels were sig-
nificantly elevated in MI WT groups but not in sham Tg and MI Tg groups (Fig. 9G and H). These results suggest 
that cardiac NOS is dysregulated in MI WT mice, and GCH1 overexpression elevates nNOS dimerization after 
MI.
Phosphorylation of NOS modulates the production of NO and superoxide from the enzyme50, 51. We deter-
mined the expression of phosphorylated NOS in post-infarction remodeled myocardium in WT and Tg mice. 
The ratios of phosphorylated nNOS (p-nNOS)/total nNOS and phosphorylated eNOS (p-eNOS)/total eNOS 
Figure 5. GTP cyclohydrolase 1 (GCH1) overexpression improves cardiac function 4 weeks after myocardial 
infarction (MI). (A) Left ventricular (LV) end-systolic pressure; (B) The rate of LV pressure rise (+dP/dt); (C) 
The LV end-diastolic pressure-volume relationship; (D) Heart weight normalized to body weight; (E) LV weight 
normalized to body weight: (F) Lung weight normalized to body weight. Figure legend: sham WT, wild-type 
mice receiving sham surgery; MI WT, wild-type mice undergoing myocardial infarction; sham Tg, transgenic 
GCH1 mice receiving sham surgery; MI Tg, transgenic GCH1 mice undergoing myocardial infarction. 
*P < 0.05 versus sham WT groups; †P < 0.05 versus MI WT groups (n = 8–10 mice/group).
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were significantly decreased from 0.71 ± 0.06 in sham WT group to 0.42 ± 0.04 in MI WT group and 0.86 ± 0.08 
in sham WT group to 0.32 ± 0.05 in MI WT group, respectively (P < 0.05, n = 5 mice/group) (Fig. 9I, J, K and L). 
Compared with sham WT groups, the ratio of p-nNOS/nNOS was elevated, and the ratio of p-eNOS/eNOS was 
not changed in sham Tg groups. There were no significant differences between MI Tg and sham WT groups in 
the ratio of p-nNOS/nNOS (P > 0.05). However, the ratio of p-eNOS/eNOS was lower in MI Tg than sham WT 
groups (P < 0.05). Phosphorylated iNOS was not detected in myocardium of sham WT mice. These results sug-
gest that GCH1 overexpression elevates p-nNOS expression in post-infarction remodeled myocardium.
Survival and parametric data. Of the 106 WT and 77 Tg mice that received sham surgery, 2 Tg and 1 WT 
mouse died in surgery. Of the 120 WT and 96 Tg mice that underwent MI surgery, 12 WT (10.0%) and 10 Tg 
(10.4%) mice did not recover from their anesthesia after surgery (Fig. S3). In the WT group, 13 additional animals 
died within 1 week of MI because of LV rupture or acute heart failure, as judged by postmortem findings (large 
infarct, cardiac dilation, pleural effusion, and severe lung congestion). Similar to the WT group, 9 mice in the Tg 
group died within 1 week of MI. Survival after MI did not differ between Tg and WT mice (P > 0.05 between MI 
Tg and MI WT groups, n = 95–104 mice/group) (Fig. S3).
Discussion
The present study identified cardiomyocyte GCH1 as a new therapeutic target for cardiac remodeling and 
dysfunction after MI. We demonstrated that cardiac GCH1 was degraded in post-infarction remodeled WT 
hearts, concomitant with increases in the thickness of interventricular septum, LV internal diameters, infarct 
size, interstitial fibrosis, superoxide, free Ca2+ in cardiomyocytes, and p-p38 MAPK; and decreases in LV ante-
rior wall thickness, fractional shortening, + dP/dt, BH4, nNOS dimerization and phosphorylation, SR Ca2+ 
release, and SR Ca2+ handling proteins (Fig. S4). Intriguingly, each of these parameters was markedly attenu-
ated in the Tg mice with cardiomyocyte-specific overexpression of human GCH1 gene. These results suggest 
that cardiomyocyte-specific overexpression of GCH1 protects SR Ca2+ handling through p38 MAPK-SR Ca2+ 
handling proteins and BH4-nNOS-SR Ca2+ handling proteins pathways and attenuates cardiac remodeling and 
dysfunction after MI.
GCH1 is constitutively expressed in cardiomyocytes, endothelial cells, and vascular smooth muscle cells14–16, 
22, 23, 52. It catalyzes the rearrangement of GTP to 7,8-dihydroneopterin triphosphate, which is subsequently con-
verted to BH4 through the sequential action of 6-pyruvoyl tetrahydrobiopterin synthase and sepiapterin reduc-
tase12. In the de novo synthesis of BH4, GCH1 is the rate-limiting enzyme, making it the major determinant of 
intracellular BH4 contents in multiple cells53. It has been well known that BH4 has multiple beneficial effects on 
Figure 6. Effects of GTP cyclohydrolase 1 (GCH1) overexpression on intracellular [Ca2+]i after myocardial 
infarction (MI). (A) Basal Ca2+ concentrations in the absence of isoproterenol; (B) The amplitude of Ca2+ 
transients elicited by electrical stimulation in the absence of isoproterenol; (C) Time to 50% decay (T50 decay) 
of Ca2+ transients in the absence of isoproterenol. (D) Original recordings of Ca2+ transients stimulated by 
electricity in the presence of isoproterenol in cardiomyocytes isolated from transgenic (Tg) and wild-type (WT) 
mice 4 weeks after MI or sham surgery. The vertical scale bar indicates 0.2 Fura-2 ratio (340/380 nM) unit, and 
the horizontal scale bar indicates 100 ms; (E) Basal [Ca2+]i in the presence of isoproterenol; (F) Ca2+ transient 
amplitude in the presence of isoproterenol; (G) T50 decay of Ca2+ transients in the presence of isoproterenol; 
(H) Figure legend. *P < 0.05 versus sham WT groups; †P < 0.05 versus MI WT groups (n = 63–66 cells/goup).
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NOS, including promoting and stabilizing the formation of homodimerization of the enzymatic proteins, an 
active form of NOS to produce NO53, 54. Accumulating evidence suggests that insufficient GCH1 proteins result in 
hypertension, cardiovascular dysfunction, and exacerbation of myocardial ischemia/reperfusion injury13, 14, 16, 21, 22. 
Thus the activity and expression of GCH1 are critical for cardiovascular health12, 13. In addition, BH4 is a key 
co-factor for tryptophan hydroxylase, phenylalanine hydroxylase, and tyrosine hydroxylase25. In humans, GCH1 
gene deficiency or mutations result in hereditary progressive dystonia, also called Segawa disease24. The patients 
with Segawa dystonia have a significantly short lifespan25.
We demonstrated that the thickness of LV anterior wall was significantly decreased, and the thickness of inter-
ventricular septum was increased in WT mice from 2 to 12 weeks after MI. Interestingly, cardiac GCH1 proteins 
were also decreased from 2 to 12 weeks after MI, whereas GCH1 mRNA levels were not significantly changed. It is 
known that the ubiquitin-proteasome system plays a central role in degradation of proteins55. Our previous work 
and that of other investigators indicate that the activation of the 26 S proteasome increases GCH1 degradation16, 56, 57. 
It is likely that decreased GCH1 in post-infarction remodeled myocardium results from increased degradation of 
GCH1 by the 26 S proteasome, rather than decreased biosynthesis of GCH1.
Our echocardiographic measurements demonstrated that WT mice developed a significant LV remode-
ling 4 weeks after MI, displaying a decrease in anterior wall thickness and increases in the thickness of inter-
ventricular septum and LV internal diameters. These results are consistent with a previous study in mice58. 
Cardiomyocyte-specific overexpression of GCH1 significantly increases LV anterior wall thickness and decreased 
the thickness of interventricular septum and internal diameters after MI. Thus, cardiac overexpression of GCH1 
plays a pivotal role in preventing the development of cardiac remodeling after MI.
Figure 7. Effects of GTP cyclohydrolase 1 (GCH1) overexpression on sarcoplasmic reticulum (SR) Ca2+ release 
and Ca2+ handling proteins after myocardial infarction (MI). (A) Original recordings of caffeine-induced Ca2+ 
release in cardiomyocytes isolated from wild-type (WT) and transgenic (Tg) mice 4 weeks after MI or sham 
surgery in 0 Na+ and 0 Ca2+ Tyrode buffer under isoproterenol stimulation. The vertical scale bar indicates 0.3 
Fura-2 ratio unit, and the horizontal bar indicates 10 s; (B) Basal [Ca2+]I in the presence of isoproterenol; (C) 
SR Ca2+ release in the presence of isoproterenol (n = 63–66 cells/group); (D) Time to 50% decay (T50 decay) 
of caffeine-induced Ca2+ transients in the presence of isoproterenol; (E) The expression of ryanodine receptors 
(RyR2) normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in Tg and WT mice 4 weeks after 
MI or sham surgery (n = 5 mice/group). Top: Wesern blot bands showing the expression of RyRs and GAPDH. 
Bottom: the ratio of RyRs/GAPDH; (F) The expression of SR Ca2+-ATPase (SERCA2a) proteins normalized 
to GAPDH. Top: Western blot bands showing the expression of SERCA2a and GAPDH. Bottom: the ratio of 
SERCA2a/GAPDH; (G) The expression of phospholamban (PLB) and SERCA2a in Tg and WT mice 4 weeks 
after MI or sham surgery. Top: Western blot bands showing the expression of PLB and SERCA2a. Bottom: the 
ratio of PLB/SERCA2a. *P < 0.05 versus sham WT groups; †P < 0.05 versus MI WT groups.
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Myocardial fibrosis contributes to abnormal cardiac remodeling, increased ventricular stiffness, and worsen-
ing LV function59. In Masson’s-stained heart sections, MI WT mice displayed large myocardial infarct size and 
a sparred ventricular septum with interstitial fibrosis, concomitant with increases in microRNA-21 levels and 
p-p38 MAPK. Cardiomyocyte-specific overexpression of GCH1 decreased myocardial fibrosis and p-p38 MAPK 
but not microRNA-21 levels after MI. Recent studies find that microRNA-21 activates fibroblasts to produce fiber 
through activation of p38 MAPK35, 60. Our results suggest that GCH1 overexpression can reduce p-p38 MAPK 
after MI through a non-microRNA-21-mediated mechanism.
We showed that cardiac contractility was impaired in MI WT mice, and GCH1 overexpression improves car-
diac contractility after MI. To elucidate the molecular mechanisms underlying reducing cardiac contractility in 
MI WT mice, we determined intracellular free Ca2+ in cardiomyocytes. It was elevated in MI WT mice, consistent 
with previous studies by Prahash and Raake, et al.61, 62. These results suggest that Ca2+ overload occurs in cardio-
myocytes isolated from WT mice. It is clear that Ca2+ overload impairs excitation-contraction coupling of myo-
cytes, thereby attenuating cardiac contractility30. GCH1 overexpression reduced intracellular [Ca2+]i after MI. 
Improved cardiac contractility by GCH1 overexpression may be attributed to reduction of Ca2+ overload after MI.
Despite Ca2+ overload in the cytoplasm, SR Ca2+ release was decreased in MI WT mice. These results are con-
sistent with the previous studies in post-infarction mouse or rat hearts41, 63. Interestingly, GCH1 overexpression 
elevated SR Ca2+ release after MI. SR Ca2+ uptake is mediated by SERCA2a, whereas RyR2 controls Ca2+ release 
from the SR43. Therefore, we determined the expression of cardiac RyR2 and SERCA2a. Consistent with changes 
in SR Ca2+ release, both RyR2 and SERCA2a were decreased in MI WT but not MI Tg mice. Thus, elevated SR 
Ca2+ release by GCH1 overexpression after MI may arise from increases in SERCA2a and RyR2.
The effect of BH4 on acute I/R injury has been studied in multiple animal models and in humans. In rats 
or pigs, the administration of either BH4 before ischemia or the combination of BH4 and L-arginine prior to 
post-ischemic reperfusion significantly reduced myocardial infarct size64, 65. In addition to the heart, the adminis-
tration of either BH4 or sepiapterin, the precursor of BH4, prior to ischemia protects the liver, kidneys, and skele-
tal muscle against I/R injury66–70. In humans, the co-administration of BH4 and L-arginine attenuates endothelial 
dysfunction induced by forearm ischemia and reperfusion in patients with coronary artery disease and type 2 
diabetes mellitus71. Collectively, BH4 plays a pivotal role in protection of tissues from acute I/R injury.
Figure 8. Effects of transgenic overexpression of human GTP cyclohydrolase 1 (GCH1) on GCH1 proteins and 
tetrahydrobiopterin in post-infarction remodeled myocardium. (A) Representative Western blot bands showing 
the expression of human and mouse GCH1 proteins and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
as control in wild-type (WT) and transgenic (Tg) mice 4 weeks after myocardial infarction (MI) or sham 
surgery; (B) Total (human + mouse) GCH1 proteins normalized to GAPDH; C: cardiac tetrahydrobiopterin 
concentrations. *P < 0.05 versus sham WT groups; †P < 0.05 versus MI WT groups; #P < 0.05 versus sham Tg 
groups (n = 5–6 mice/group).
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 3093  | DOI:10.1038/s41598-017-03234-6
In the current study, GCH1 overexpression elevated cardiac BH4 concentrations in both normal and 
post-infarction myocardium. These results are not surprising given that GCH1 is the first and rate-limiting 
enzyme in the de novo synthesis of BH412. A growing body of research indicates that BH4 is a potential thera-
peutic target for cardiovascular disease, such as hypertension, myocardial ischemia/reperfusion injury, pressure 
overload-induced cardiac hypertrophy, and diabetic vascular dysfunction13, 38, 46, 72, 73. Despite controversy, BH4 
is generally reported to increase eNOS coupling and phosphorylation, elevate NO production, increase tissue 
cGMP levels, suppress oxidative/nitrosative stress, improve intracellular Ca2+ homeostasis, elevates SR Ca2+ 
cycling, and inhibit inflammation13, 38, 46, 74, 75. It is possible that above BH4–mediated signaling pathways are 
involved in the favorable effects of GCH1 overexpression on post-infarction remodeled myocardium.
We demonstrated that cardiac remodeling after MI resulted in increases in nNOS, eNOS, and iNOS mono-
mers. These results were consistent with the previous studies in post-infarction rat hearts76–78. It is noteworthy 
that NOS produces NO only as a homodimer, whereas NOS is not active as a monomer79. Thus, we determined 
the expression of nNOS and eNOS dimers in mouse myocardium after MI. The ratios of nNOS dimers/monomers 
and eNOS dimers/monomers were significantly reduced in WT mice after MI. GCH1 overexpression prevented 
decreases in the ratio of nNOS dimers/monomers but not eNOS dimers/monomers and increased iNOS mono-
mers in the heart after MI. The differential regulatory effects of GCH1 overexpression on nNOS, eNOS, and iNOS 
in post-infarction myocardium may be related to the fact that most of nNOS and iNOS exist in cardiac myocytes, 
and eNOS is mainly expressed in vascular endothelial cells28, 74, 77.
One limitation of this study is lack of pharmacological approaches to testing the potential of GCH1 preser-
vation to improve cardiac remodeling and dysfunction after MI. The current study demonstrated that transgenic 
overexpression of human GCH1 in cardiomyocytes prevented the development of LV remodeling after MI. In this 
genetically engineered mouse, cardiac BH4 levels were significantly elevated by about 25 folds in sham-operated 
mice. Whether pharmacological supplementation of BH4 can also elevate cardiac BH4 to similar levels in intact 
Figure 9. GTP cyclohydrolase 1 (GCH1) overexpression differentially regulates nitric oxide synthase (NOS) 
isoforms in post-infarction remodeled myocardium. (A) Representative Western blot bands showing the 
expression of dimeric and monomeric neuronal NOS (nNOS) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as loading control in wild-type (WT) and transgenic (Tg) mice 4 weeks after myocardial infarction 
(MI) or sham surgery (sham); (B) The ratio of nNOS dimers/monomers; (C) Representative Western blot bands 
of dimeric and monomeric endothelial NOS (eNOS) and GAPDH; (D) The ratio of eNOS dimers/monomers; 
(E) Western blot bands showing the expression of inducible NOS (iNOS) monomers and GAPDH; (F) iNOS 
monomers normalized to GAPDH; (G) NOx levels; (H) superoxide levels; (I) representative Western blot bands 
showing the expresiion of phosphorylated nNOS (p-nNOS), nNOS, and GAPDH; (J) The ratio of p-nNOS/
total nNOS; (K) Western blot bands of phosphorylated eNOS (p-eNOS), eNOS, and GAPDH; (L) the ratio 
of phosphorylated eNOS (p-eNOS)/total eNOS. *P < 0.05 versus sham WT groups; †P < 0.05 versus MI WT 
groups; #P < 0.05 versus sham Tg groups (n = 5 mice/group).
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animals remains elusive. In addition, transgenic overexpression of GCH1 resulted in an increase in the expression 
of cardiac RyRs which are responsible for SR Ca2+ release to trigger myocyte contraction. Whether pharmaco-
logical supplementation of BH4 can produce such beneficial effect is unknown. Nonetheless, our current study 
suggests that a combination of BH4 agents with increased expression of SR Ca2+ handling proteins has a beneficial 
effect on cardiac remodeling after MI. It is clear that 26 S proteasome is responsible for degradation of GCH1 
proteins56, 57. 26 S proteasome can selectively recognize specific proteins to degradation through its 19 S regulatory 
particles80. This property of the 26 S proteasome suggests that there is a possibility to develop 26 S proteasome 
inhibitors with specificity towards targeting GCH181. Such a 26 S proteasome inhibitor may be useful in the clin-
ical treatment of post-infarction cardiac remodeling and dysfunction.
In summary, our results demonstrate the importance of cardiac GCH1 in reducing cardiac remodeling and 
dysfunction and interstitial fibrosis after MI in the mouse (Fig. S4). Cardiomyocyte-specific overexpression of 
GCH1 elevates BH4 levels and nNOS dimerization and preserves intracellular Ca2+ handling, thereby diminish-
ing cardiac remodeling and dysfunction after MI (Fig. S4). The present study suggests new strategies for prevent-
ing cardiac remodeling and dysfunction in patients after MI.
Methods
Animals. The Tg mice with cardiomyocyte-specific overexpression of human GCH1 gene on a C57BL/6 back-
ground were developed under the control of the α-myosin heavy chain promoter, as described previously14. The 
Tg mice were identified by the presence of human GCH1 gene using polymerase chain reaction (PCR) on tail-de-
rived genomic DNA14. C57BL/6 WT littermates were used as controls for the Tg mice. The animal care and all 
experimental procedures were performed in accordance with the NIH Guide for the Care and Use of Laboratory 
Animals (Institute for Laboratory Animal Research, National Academy of Sciences, USA, 8th edition, 2011), and 
experimental protocols were approved by the IACUC at the Medical College of Wisconsin (Milwaukee, WI, 
USA).
Induction of MI. Male WT and Tg mice at the ages of 8–10 weeks were anesthetized by intraperitoneal injec-
tion of 80 mg/kg sodium pentobarbital. A left thoracotomy was performed between the 4th and 5th ribs33. The left 
anterior coronary artery was permanently ligated with an 8–0 silk suture near its origin between the pulmonary 
outflow tract and the edge of the left atrium, as described38.
Transthoracic echocardiography. Animals were sedated by the inhalation of oxygen with 1.5% isoflu-
rane. Echocardiography was performed with a VisualSonics Vevo 770 High-resolution Imaging System (Toronto, 
Canada) equipped with a 30 MHz transducer (Scanhead RMV 707), as described previously37, 82. M-mode images 
were recorded from the short axis 2-chamber view at the papillary muscle level.
PCR analysis of GCH1 mRNA. The LV was homogenized at 4 °C for PCR analysis of GCH1 mRNA, as 
described16.
Histopathological examination of mouse hearts. The hearts were sliced transversely from the apex 
to the basal part of the LV at 6 μm-thickness for measurements of LV morphology and interstitial fibrosis or 
4 μm-thickness for measurements of myocyte cross-sectional area with the interval of 300 μm between each sec-
tion16. All sections were stained with Masson’s trichrome. Infarct size was expressed as total infarct circumference 
divided by total LV circumference.
Real-time reverse transcriptional-polymerase chain reaction analysis of microRNA-21. Heart 
tissues were collected from both the septum and the LV free wall in sham WT or Tg mice and from non-infarct 
myocardium in MI mice 4 weeks after surgery. Homogenized tissues were used in real-time quantitative reverse 
transcriptional-polymerase chain reaction (qRT-PCR) analysis of microRNA-2182.
Isolated Langendorff-perfused hearts. Mouse hearts were quickly mounted on an isolated Langendorff 
apparatus and perfused retrogradely through the aorta at a constant pressure of 80 mmHg with Krebs-Henseleit 
buffer, as described37, 83. LV end-diastolic pressure was set to 5 mmHg by adjusting the volume of the intracar-
diac balloon. After 30 min of stabilization, LV systolic pressure and + dP/dt were determined37. The intracardiac 
balloon volume was set at zero volume, inflated to 20 µl, and subsequently increased in 5-µl intervals using an 
air-tight Hamilton syringe until 70 µl to obtain LV end-diastolic pressure-volume relationship84.
Measurements of cardiomyocyte [Ca2+]i. Cardiomyocytes isolated from mice 4 weeks after MI or sham 
surgery were loaded with Fura-2 AM (Fura-2 acetoxymethyl ester) at a concentration of 5 µM, as described16. 
The cells were stimulated in an electric field at 0.5 Hz for 30 s followed by a period of 20 s without stimulation and 
continuously perfused with a solution containing 1.0 mM CaCl2 without and with 20 nM isoproterenol85. The 
ratio of the emitted fluorescence at the two excitation wavelengths (340/380 nM ratio) was calculated to provide 
an index of intracellular [Ca2+]i.
Measurements of SR Ca2+ release. SR Ca2+ release was induced by rapid application of 10 mM caffeine 
to the cells in the presence of 0 Na+ and 0 Ca2+ Tyrode buffer to inhibit Na+-Ca2+ exchange, as described16. The 
protocol was repeated after 100 s exposure to 20 nM isoproterenol added to Tyrode buffer.
Western blot analysis. The LV homogenates that contained 50 µg of protein were applied to 7.5% sodium 
dodecyl sulfate (SDS)-polyacrylamide gel and subjected to immunoblot analysis by incubation with primary 
antibodies against human GCH1, mouse GCH1, p38 MAPK, p-p38 MAPK (tryptophan180/tyrosine 182), nNOS, 
eNOS, iNOS, RyR2, SERCA2a, T-PLB, p-PLB at serine 16, and GAPDH at 4 °C, as described82, 86. The membrane 
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was then incubated with the appropriate anti-mouse or anti-rabbit secondary antibody. Immunoreactive bands 
were visualized by enhanced chemiluminescence followed by densitometric analysis using image acquisition and 
analysis software (Image J, National Institutes of Health, Baltimore, MD, USA).
Assay of BH4. BH4 was quantified in LV tissue homogenates by HPLC with electrochemical detection (ESA 
Biosciences CoulArray® system Model 542, Chelmsford, MA, USA)75, 83. Authentic BH4 solutions (10–100 nM) 
were used as standards, and sample concentrations were normalized to protein content measured by the bicin-
choninic acid protein assay.
Measurements of NO and O2•−. Tissue NO and its metabolite products (nitrate and nitrite) in the 
supernatant, collectively known as NOx, were assayed using a NO chemiluminescence analyzer (Siever 280i NO 
Analyzer)14. Lucigenin, a compound that emits light upon interaction with O2•−, was used to quantify the O2•− 
production from myocardium16. The data were presented in relative light units (RLUs) per mg protein.
Statistics. All data are expressed as mean ± S.E.M. Statistical analysis was performed with one-way ANOVA 
followed by Bonferroni post-hoc test for multiple comparisons of multiple group means or with Student’s t-test 
for comparisons between two group means. Repeated-measures ANOVA was used to compare the differences 
in heart surface area, echocardiographic parameters, GCH1 mRNA, GCH1 proteins, and LV end-diastolic 
pressure-volume relationships at different time points. A value of P < 0.05 was considered statistically different.
Data availability. The data that support the findings in this study are available from the corresponding 
author on request.
References
 1. Mozaffarian, D. et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 
133, e38–360 (2016).
 2. Townsend, N. et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 0, 14 (2016).
 3. Konstam, M. A., Kramer, D. G., Patel, A. R., Maron, M. S. & Udelson, J. E. Left ventricular remodeling in heart failure: current 
concepts in clinical significance and assessment. JACC. Cardiovasc Imag 4, 98–108 (2011).
 4. Galli, A. & Lombardi, F. Postinfarct left ventricular remodelling: a prevailing cause of heart failure. Cardiol Res Practice 2016, 
2579832 (2016).
 5. Nayor, M., Enserro, D. M., Vasan, R. S. & Xanthakis, V. Cardiovascular health status and incidence of heart failure in the 
Framingham offspring study. Circ Heart Fail 9, e002416 (2016).
 6. Daubert, M. A. et al. High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and 
improved outcomes in patients with coronary artery disease and reduced ejection fraction. Am Heart J 170, 550–558 (2015).
 7. Jhund, P. S. & McMurray, J. J. Heart failure after acute myocardial infarction: a lost battle in the war on heart failure? Circulation 118, 
2019–2021 (2008).
 8. Minicucci, M. F., Azevedo, P. S., Polegato, B. F., Paiva, S. A. & Zornoff, L. A. Heart failure after myocardial infarction: clinical 
implications and treatment. Clin Cardiol 34, 410–414 (2011).
 9. Tang, X. L. et al. Long-term outcome of administration of c-kitPOS cardiac progenitor cells after acute myocardial infarction: 
transplanted cells do not become cardiomyocytes, but structural and functional improvement and proliferation of endogenous cells 
persist for at least one year. Circ Res 118, 1091–1105 (2016).
 10. Zwetsloot, P. P. et al. Cardiac stem cell treatment in myocardial infarction: a systematic review and meta-analysis of preclinical 
studies. Circ Res 118, 1223–1232 (2016).
 11. Gyongyosi, M., Wojakowski, W., Navarese, E. P. & Moye, L. A. Meta-analyses of human cell-based cardiac regeneration therapies: 
controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ Res 118, 1254–1263 (2016).
 12. Bendall, J. K., Douglas, G., McNeill, E., Channon, K. M. & Crabtree, M. J. Tetrahydrobiopterin in cardiovascular health and disease. 
Antioxid Redox Signal 20, 3040–3077 (2014).
 13. Ceylan-Isik, A. F. et al. Metallothionein abrogates GTP cyclohydrolase I inhibition-induced cardiac contractile and morphological 
defects: role of mitochondrial biogenesis. Hypertension 53, 1023–1031 (2009).
 14. Ge, Z. D. et al. Cardiac-specific overexpression of GTP cyclohydrolase 1 restores ischaemic preconditioning during hyperglycaemia. 
Cardiovasc Res 91, 340–349 (2011).
 15. Carnicer, R. et al. Cardiomyocyte GTP cyclohydrolase 1 and tetrahydrobiopterin increase NOS1 activity and accelerate myocardial 
relaxation. Circ Res 111, 718–727 (2012).
 16. Wu, H. E. et al. Cardiomyocyte GTP cyclohydrolase 1 protects the heart against diabetic cardiomyopathy. Sci Rep 6, 27825 (2016).
 17. Cederfjall, E., Broom, L. & Kirik, D. Controlled striatal DOPA production from a gene delivery system in a rodent model of 
Parkinson’s disease. Mol Ther 23, 896–906 (2015).
 18. Wei, T. et al. Metabonomic analysis of potential biomarkers and drug targets involved in diabetic nephropathy mice. Sci Rep 5, 11998 
(2015).
 19. Belik, J. et al. Pulmonary hypertension in the newborn GTP cyclohydrolase I-deficient mouse. Free Radic Biol Med 51, 2227–2233 
(2011).
 20. Zhao, Y., Wu, J., Zhu, H., Song, P. & Zou, M. H. Peroxynitrite-dependent zinc release and inactivation of guanosine 5’-triphosphate 
cyclohydrolase 1 instigate its ubiquitination in diabetes. Diabetes 62, 4247–4256 (2013).
 21. Chuaiphichai, S. et al. Cell-autonomous role of endothelial GTP cyclohydrolase 1 and tetrahydrobiopterin in blood pressure 
regulation. Hypertension 64, 530–540 (2014).
 22. Li, P. et al. Inhibition of aberrant microRNA-133a expression in endothelial cells by statin prevents endothelial dysfunction by 
targeting GTP cyclohydrolase 1 in vivo. Circulation 134, 1752–1765 (2016).
 23. Chuaiphichai, S. et al. A key role for tetrahydrobiopterin-dependent endothelial NOS regulation in vascular resistance arteries: 
studies in endothelial cell tetrahydrobiopterin-deficient Mice. Br J Pharmacol 2017, 13728 (2017).
 24. Ikeda, T. et al. Segawa disease with a novel heterozygous mutation in exon 5 of the GCH-1 gene (E183K). Brain Dev 31, 173–175 
(2009).
 25. Wijemanne, S. & Jankovic, J. Dopa-responsive dystonia–clinical and genetic heterogeneity. Nat Rev Neurol 11, 414–424 (2015).
 26. Baotic, I. et al. Isoflurane favorably modulates guanosine triphosphate cyclohydrolase-1 and endothelial nitric oxide synthase during 
myocardial ischemia and reperfusion injury in rats. Anesthesiology 123, 582–589 (2015).
 27. Shimizu, Y. et al. Sodium sulfide attenuates ischemic-induced heart failure by enhancing proteasomal function in an Nrf2-dependent 
manner. Circ Heart Fail 9, e002368 (2016).
 28. Forstermann, U. & Sessa, W. C. Nitric oxide synthases: regulation and function. Eur Heart J 33, 829–837 (2012). 837a–837d.
www.nature.com/scientificreports/
1 4Scientific RepoRts | 7: 3093  | DOI:10.1038/s41598-017-03234-6
 29. Lucas, A. et al. Gadd45γ regulates cardiomyocyte death and post-myocardial infarction left ventricular remodelling. Cardiovasc Res 
108, 254–267 (2015).
 30. Davlouros, P. A. et al. Calcium homeostasis and kinetics in heart failure. Med Chem 12, 151–161 (2016).
 31. Raj, P. et al. Resveratrol is equipotent to perindopril in attenuating post-infarct cardiac remodeling and contractile dysfunction in 
rats. J Nutr Biochem 28, 155–163 (2016).
 32. Ge, Z. D. et al. Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5’-N-methylcarboxamide] reduces ischemia/reperfusion 
injury in mice by activating the A3 adenosine receptor. J Pharmacol Exp Ther 319, 1200–1210 (2006).
 33. Ge, Z. D., van der Hoeven, D., Maas, J. E., Wan, T. C. & Auchampach, J. A. A3 adenosine receptor activation during reperfusion 
reduces infarct size through actions on bone marrow-derived cells. J Mol Cell Cardiol 49, 280–286 (2010).
 34. Lin, L. Y. et al. Myocardial regional interstitial fibrosis is associated with left intra-ventricular dyssynchrony in patients with heart 
failure: a cardiovascular magnetic resonance study. Sci Rep 6, 20711 (2016).
 35. Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 
980–984 (2008).
 36. Arabacilar, P. & Marber, M. The case for inhibiting p38 mitogen-activated protein kinase in heart failure. Front Pharmacol 6, 102 
(2015).
 37. Ge, Z. D. et al. Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition 
by an endothelial nitric oxide synthase-dependent mechanism. Anesthesiology 112, 73–85 (2010).
 38. Baumgardt, S. L. et al. Chronic co-administration of sepiapterin and L-citrulline ameliorates diabetic cardiomyopathy and 
myocardial ischemia/reperfusion injury in obese type 2 diabetic mice. Circ Heart Fail 9, e002424 (2016).
 39. Fearnley, C. J., Roderick, H. L. & Bootman, M. D. Calcium signaling in cardiac myocytes. Cold Spring Harb Perspect Biol 3, a004242 
(2011).
 40. Gorski, P. A., Ceholski, D. K. & Hajjar, R. J. Altered myocardial calcium cycling and energetics in heart failure–a rational approach 
for disease treatment. Cell Metab 21, 183–194 (2015).
 41. Sadredini, M. et al. β-Adrenoceptor stimulation reveals Ca2+ waves and sarcoplasmic reticulum Ca2+ depletion in left ventricular 
cardiomyocytes from post-infarction rats with and without heart failure. PloS ONE 11, e0153887 (2016).
 42. Rapacciuolo, A. et al. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-
overload cardiac hypertrophy. J Am Coll Cardiol 38, 876–882 (2001).
 43. Feridooni, H. A., Dibb, K. M. & Howlett, S. E. How cardiomyocyte excitation, calcium release and contraction become altered with 
age. J Mol Cell Cardiol 83, 62–72 (2015).
 44. Hayward, C., Banner, N. R., Morley-Smith, A., Lyon, A. R. & Harding, S. E. The current and future landscape of SERCA gene therapy 
for heart failure: a clinical perspective. Human Gene Ther 26, 293–304 (2015).
 45. Soller, K. J., Yang, J., Veglia, G. & Bowser, M. T. Reversal of phospholamban inhibition of the sarco(endo)plasmic reticulum Ca2+-
ATPase (SERCA) using short protein interacting RNAs and oligonucleotide analogs. J Biol Chem 291, 21510–21518 (2016).
 46. Hashimoto, T. et al. Tetrahydrobiopterin protects against hypertrophic heart disease independent of myocardial nitric oxide 
synthase coupling. J Am Heart Ass 5, e003208 (2016).
 47. Dawson, D. et al. nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after 
myocardial infarction. Circulation 112, 3729–3737 (2005).
 48. Silberman, G. A. et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 121, 519–528 (2010).
 49. Roe, N. D. & Ren, J. Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vasc Pharmacol 57, 168–172 
(2012).
 50. Dimmeler, S. et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601–605 
(1999).
 51. Chen, C. A., Druhan, L. J., Varadharaj, S., Chen, Y. R. & Zweier, J. L. Phosphorylation of endothelial nitric-oxide synthase regulates 
superoxide generation from the enzyme. J Biol Chem 283, 27038–27047 (2008).
 52. Alp, N. J. et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted 
transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 112, 725–735 (2003).
 53. Crabtree, M. J. et al. Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both 
tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I 
expression. J Biol Chem 284, 1136–1144 (2009).
 54. Bendall, J. K. et al. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, 
and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS 
overexpression. Circ Res 97, 864–871 (2005).
 55. Yu, X. & Kem, D. C. Proteasome inhibition during myocardial infarction. Cardiovasc Res 85, 312–320 (2010).
 56. Xu, J. et al. Proteasome-dependent degradation of guanosine 5’-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency 
in diabetes mellitus. Circulation 116, 944–953 (2007).
 57. Whitsett, J., Picklo, M. J. Sr. & Vasquez-Vivar, J. 4-Hydroxy-2-nonenal increases superoxide anion radical in endothelial cells via 
stimulated GTP cyclohydrolase proteasomal degradation. Arterioscler Thromb Vasc Biol 27, 2340–2347 (2007).
 58. Gao, X. M., Dart, A. M., Dewar, E., Jennings, G. & Du, X. J. Serial echocardiographic assessment of left ventricular dimensions and 
function after myocardial infarction in mice. Cardiovasc Res 45, 330–338 (2000).
 59. Daskalopoulos, E. P., Dufeys, C., Bertrand, L., Beauloye, C. & Horman, S. AMPK in cardiac fibrosis and repair: Actions beyond 
metabolic regulation. J Mol Cell Cardiol 91, 188–200 (2016).
 60. Liu, S. et al. Micro-RNA 21 targets dual specific phosphatase 8 to promote collagen synthesis in high glucose-treated primary cardiac 
fibroblasts. Can J Cardiol 30, 1689–1699 (2014).
 61. Prahash, A. J., Gupta, S. & Anand, I. S. Myocyte response to β-adrenergic stimulation is preserved in the noninfarcted myocardium 
of globally dysfunctional rat hearts after myocardial infarction. Circulation 102, 1840–1846 (2000).
 62. Raake, P. W. et al. Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to 
adverse alterations and remodeling after myocardial infarction. Circulation 125, 2108–2118 (2012).
 63. Schuster, I. et al. Cardiomyocyte-specific overexpression of oestrogen receptor beta improves survival and cardiac function after 
myocardial infarction in female and male mice. Clinl Sci 130, 365–376 (2016).
 64. Wajima, T., Shimizu, S., Hiroi, T., Ishii, M. & Kiuchi, Y. Reduction of myocardial infarct size by tetrahydrobiopterin: possible 
involvement of mitochondrial KATP channels activation through nitric oxide production. J Cardiovasc Pharmacol 47, 243–249 
(2006).
 65. Tratsiakovich, Y. et al. Myocardial protection by co-administration of L-arginine and tetrahydrobiopterin during ischemia and 
reperfusion. Int J Cardiol 169, 83–88 (2013).
 66. Hara, Y. et al. Beneficial effect of tetrahydrobiopterin on the survival of rats exposed to hepatic ischemia-reperfusion injury. 
Transplant Proc 37, 442–444 (2005).
 67. Hara, Y., Teramoto, K., Ishidate, K. & Arii, S. Cytoprotective function of tetrahydrobiopterin in rat liver ischemia/reperfusion injury. 
Surgery 139, 377–384 (2006).
 68. Dai, Y., Cui, J., Cun, Y. & Shi, A. Tetrahydrobiopterin ameliorates hepatic ischemia-reperfusion Injury by coupling with eNOS in 
mice. J Surg Res 176, e65–71 (2012).
www.nature.com/scientificreports/
1 5Scientific RepoRts | 7: 3093  | DOI:10.1038/s41598-017-03234-6
 69. Legrand, M., Kandil, A., Payen, D. & Ince, C. Effects of sepiapterin infusion on renal oxygenation and early acute renal injury after 
suprarenal aortic clamping in rats. J Cardiovasc Pharmacol 58, 192–198 (2011).
 70. Wang, W. Z., Fang, X. H., Stephenson, L. L., Khiabani, K. T. & Zamboni, W. A. Effects of supplementation of BH4 after prolonged 
ischemia in skeletal muscle. Microsurgery 27, 200–205 (2007).
 71. Settergren, M., Bohm, F., Malmstrom, R. E., Channon, K. M. & Pernow, J. L-arginine and tetrahydrobiopterin protects against 
ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease. 
Atherosclerosis 204, 73–78 (2009).
 72. Xie, L., Talukder, M. A., Sun, J., Varadharaj, S. & Zweier, J. L. Liposomal tetrahydrobiopterin preserves eNOS coupling in the post-
ischemic heart conferring in vivo cardioprotection. J Mol Cell Cardiol 86, 14–22 (2015).
 73. Yoshioka, K. et al. Sepiapterin prevents left ventricular hypertrophy and dilatory remodeling induced by pressure overload in rats. 
Am J Physiol Heart Circ Physiol 309, H1782–1791 (2015).
 74. Otani, H. The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal 11, 1913–1928 (2009).
 75. Sethumadhavan, S. et al. Increasing tetrahydrobiopterin in cardiomyocytes adversely affects cardiac redox state and mitochondrial 
function independently of changes in NO production. Free Radic Biol Med 93, 1–11 (2016).
 76. Zhang, Y. H. & Casadei, B. Sub-cellular targeting of constitutive NOS in health and disease. J Mol Cell Cardiol 52, 341–350 (2012).
 77. Zhang, Y. H., Jin, C. Z., Jang, J. H. & Wang, Y. Molecular mechanisms of neuronal nitric oxide synthase in cardiac function and 
pathophysiology. J Physiol 592, 3189–3200 (2014).
 78. Tsutsui, M. et al. Significance of nitric oxide synthases: Lessons from triple nitric oxide synthases null mice. J Pharmacol Sci 127, 
42–52 (2015).
 79. Daff, S. NO synthase: structures and mechanisms. Nitric oxide 23, 1–11 (2010).
 80. Lecker, S. H., Goldberg, A. L. & Mitch, W. E. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. 
J Am Soc Nephrol 17, 1807–1819 (2006).
 81. Inobe, T. & Genmei, R. Inhibition of the 26S proteasome by peptide mimics of the coiled-coil region of its ATPase subunits. Biochem 
Biophys Res Commun 468, 143–150 (2015).
 82. Qiao, S. et al. MicroRNA-21 mediates isoflurane-induced cardioprotection against ischemia-reperfusion injury via Akt/nitric oxide 
synthase/mitochondrial permeability transition pore pathway. Anesthesiology 123, 786–798 (2015).
 83. Leucker, T. M. et al. Impairment of endothelial-myocardial interaction increases the susceptibility of cardiomyocytes to ischemia/
reperfusion injury. PloS ONE 8, e70088 (2013).
 84. Maczewski, M. & Mackiewicz, U. Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the 
post-infarction rat heart. Cardiovasc Res 79, 42–51 (2008).
 85. Makarewich, C. A. et al. Transient receptor potential channels contribute to pathological structural and functional remodeling after 
myocardial infarction. Circ Res 115, 567–580 (2014).
 86. Vladic, N. et al. Decreased tetrahydrobiopterin and disrupted association of Hsp90 with eNOS by hyperglycemia impair myocardial 
ischemic preconditioning. Am J Physiol Heart Circ Physiol 301, H2130–2139 (2011).
Acknowledgements
We are grateful to Drs John A. Auchampach, Ph.D., Garret J Gross, Ph.D., and Tina C. Wan, Ph.D. (Department 
of Pharmacology and Toxicology, Medical College of Wisconsin) for their equipment. This work was supported in 
part by the National Institutes of Health research grant GM 066730 and HL 063705 from the United States Public 
Health Services, Bethesda, Maryland and the Pilot Grant from Research Affairs Committee, Medical College of 
Wisconsin.
Author Contributions
Z.-D.G. conceived and designed the experiment. J.R.K., Z.J.B., and D.C.W. directed the study and advised on parts 
of the study. Z.-D.G. made myocardial infarction in wild-type and Tg mice, used echocardiography to evaluate 
the mice, and performed isolated heart experiments. Y.L., Y.S., and Z.X. conducted Western blot analysis. S.L.B., 
J.V.-V., and S.Q. generated the Tg mice and took care of mice after surgery. J.F., Y.L., and Z.-D.G. performed 
P.C.R. analysis, biochemical measurements, and histopathological analyses. Y.S. and J.V.-V. conducted HPLC 
experiments. S.Q. and Z.-D.G. isolated cardiomyocytes from mice and measured intracellular Ca2+ signaling. 
Z.-D.G. drafted the manuscript. All authors analyzed the results and edited the manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-03234-6
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
